Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PNMA2 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PNMA2 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PLAUR Biologics Sequence Review Report 2026: Urokinase plasminogen activator surface receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PLAUR Biologics Sequence Review Report 2026: Urokinase plasminogen activator surface receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLAUR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PGF Biologics Sequence Review Report 2026: Placenta growth factor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PGF Biologics Sequence Review Report 2026: Placenta growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PEX5 Biologics Sequence Review Report 2026: Peroxisomal targeting signal 1 receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PEX5 Biologics Sequence Review Report 2026: Peroxisomal targeting signal 1 receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PEX5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PEAR1 Biologics Sequence Review Report 2026: Platelet endothelial aggregation receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PEAR1 Biologics Sequence Review Report 2026: Platelet endothelial aggregation receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PEAR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PDCD1LG2 Biologics Sequence Review Report 2026: Programmed cell death 1 ligand 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PDCD1LG2 Biologics Sequence Review Report 2026: Programmed cell death 1 ligand 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PDCD1LG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PAGE4 Biologics Sequence Review Report 2026: P antigen family member 4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PAGE4 Biologics Sequence Review Report 2026: P antigen family member 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PAGE4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OXGR1 Biologics Sequence Review Report 2026: 2-oxoglutarate receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OXGR1 Biologics Sequence Review Report 2026: 2-oxoglutarate receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OXGR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OSMR Biologics Sequence Review Report 2026: Oncostatin-M-specific receptor subunit beta Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OSMR Biologics Sequence Review Report 2026: Oncostatin-M-specific receptor subunit beta Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OSMR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR8G1 Biologics Sequence Review Report 2026: Olfactory receptor 8G1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR8G1 Biologics Sequence Review Report 2026: Olfactory receptor 8G1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR8G1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR7D4 Biologics Sequence Review Report 2026: Olfactory receptor 7D4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR7D4 Biologics Sequence Review Report 2026: Olfactory receptor 7D4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR7D4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR6A2 Biologics Sequence Review Report 2026: Olfactory receptor 6A2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR6A2 Biologics Sequence Review Report 2026: Olfactory receptor 6A2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR6A2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →